Aakaar Medical Technologies has announced its entry into the manufacturing of Aesthetics Devices, following a decision taken by its Board of Directors in their meeting held on May 15, 2026. The development was disclosed to the National Stock Exchange of India Limited under Regulation 30(4)(i)(d) read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and in accordance with the company's Policy on Determination of Materiality of Events and Information.

New Manufacturing Facility in Pune

The company has decided to lease a premises in Pune for the purpose of contract manufacturing of Aesthetics Devices. This marks a new business vertical for Aakaar Medical Technologies, expanding its product portfolio into the aesthetics segment. The arrangement involves no special rights such as the right to appoint directors, first right to share subscription in case of issuance of shares, or the right to restrict any change in capital structure.

The key details of the disclosure, as filed under Annexure A pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, are summarised below:

Regulatory Compliance and Disclosure

The disclosure was made by Company Secretary and Compliance Officer Anoopkumar Pillai on behalf of Aakaar Medical Technologies. The filing confirms that the transaction does not constitute a related party transaction and that the parties involved bear no relationship to the promoter, promoter group, or group companies. No shares are being issued, and no loan agreements are associated with this arrangement.

The announcement underscores the company's commitment to regulatory transparency as it pursues this new manufacturing initiative in the medical aesthetics space.

Aakaar Medical Technologies has announced the appointment of M/s. NAM & ASSOCIATES, a Peer Reviewed Firm of Company Secretaries in Practice, as its Secretarial Auditors for a term of 5 consecutive years. The decision was approved by the Board of Directors at its meeting held on Friday, May 15, 2026, which commenced at 3:35 P.M. IST and concluded at 4:00 P.M. IST, pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Appointment Details

The appointment was made on the recommendation of the Audit Committee and is subject to approval of the shareholders at the ensuing Annual General Meeting. The key details of the appointment are outlined below:

Profile of the Firm

Ms. Neha Marathe, the key professional associated with M/s. NAM & ASSOCIATES, is a fellow member of the Institute of Company Secretaries of India (ICSI) with 10 years of practice experience. Her academic qualifications include a Graduation Degree in Foreign Trade (BFT) and a Post Graduate Diploma in Foreign Trade from Pune University. Her areas of expertise span across:

• Corporate Laws
• Foreign Exchange Laws
• Audit under Company Law and allied laws
• Secretarial Audits of listed and unlisted companies under the Companies Act, 2013
• Corporate restructuring

Ms. Marathe is also registered as an Independent Director on the portal of the Indian Institute of Corporate Affairs.

Regulatory Compliance

The disclosure has been made in accordance with Clause 7 of Para A of Part A of Schedule III of the SEBI Listing Regulations, read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024. The announcement was communicated to the National Stock Exchange of India Limited as part of the company's compliance obligations under the applicable SEBI regulations. Company Secretary and Compliance Officer Anoopkumar V. Pillai signed and submitted the disclosure on behalf of Aakaar Medical Technologies Ltd.